Table of Contents Understanding Mounjaro and Its Gastrointestinal Effects Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities
Coffee-friendly combo Grande Caff Latte with no syrup + Egg White Egg Bites This gives protein from both milk and egg bites without relying on a sweet drink
Han E, Lee YH, Lee BW, Kang ES, Cha BS (2020) Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
In clinical trials, patients lost 12 percent of their body weight on average, in line with the original Ozempic injection, but a smidge lower than Mounjaro, Zepbound, and some of the more recent entries into this drug class
